

REMARKS

The Applicants are kindly requesting the cancellation of Claims 1-25 and the entry of new Claims 26-61. New Claims 26-61 are based on cancelled Claims 1-25. Support for new Claims 26-61 can be found throughout the Specification. No new matter is being added.

The Amendments to the Specifications are made solely to add SEQ ID NO's to page 14 of the Specification in order to comply with U.S. practice on sequence listings. The sequences were present in the PCT application, but were considered so minor as to not need sequence listing numbers. Applicants request the entry of the amendment adding SEQ ID NO's to these minor sequences. These sequences have been added to the Sequence Listing in both print and computer readable forms.

Applicant authorizes the Commissioner to charge all fees due to Deposit Account 19-0134. Applicant also requests that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address.
Thank you for your assistance with this matter.

Respectfully submitted,



David L. Marks
Attorney for Applicants
Reg. No. 37,881

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7922

Date: January 4, 2006